Mount Sinai and Hackensack Meridian have joined Memorial Sloan Kettering – now recruiting patients in SLSG12D-P2 clinical trial

September 6, 2018 РSilenseed announced that the Medical Centers Mount Sinai and Hackensack Meridian have joined Memorial Sloan Kettering and are now recruiting patients in the Phase 2 SLSG12D-P2 clinical trial in Locally Advanced Pancreatic Cancer (LAPC). Principle investigators in Mount Sinai are Celina Ang, MD and Christopher J DiMaio, MD; Principle investigators in Hackensack Meridiani are Martin E Gutierrez, MD and Rosario Ligresti, MD, FASGE.
 
 

Share this post

Share on facebook
Share on google
Share on twitter
Share on linkedin
Share on pinterest
Share on print
Share on email